Chris H. Takimoto, M.D., Ph.D., F.A.C.P
2022
In 2022, Chris H. Takimoto, M.D., Ph.D., F.A.C.P earned a total compensation of $1.8M as Chief Medical Officer at IGM Biosciences, a 78% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $217,217 |
|---|---|
| Option Awards | $928,290 |
| Salary | $467,736 |
| Stock Awards | $213,875 |
| Total | $1,827,118 |
FACP received $928.3K in option awards, accounting for 51% of the total pay in 2022.
FACP also received $217.2K in non-equity incentive plan, $467.7K in salary and $213.9K in stock awards.
Rankings
In 2022, Chris H. Takimoto, M.D., Ph.D., F.A.C.P's compensation ranked 1,900th out of 5,717 executives tracked by ExecPay. In other words, FACP earned more than 66.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,900 out of 5,717 | 67th |
Division Manufacturing | 1,004 out of 3,111 | 68th |
Major group Chemicals And Allied Products | 420 out of 1,410 | 70th |
Industry group Drugs | 385 out of 1,311 | 71st |
Industry Pharmaceutical Preparations | 276 out of 957 | 71st |
Source: SEC filing on April 27, 2023.
FACP's colleagues
We found two more compensation records of executives who worked with Chris H. Takimoto, M.D., Ph.D., F.A.C.P at IGM Biosciences in 2022.